Updated findings from the phase 2/3 RELATIVITY-047 trial (NCT03470922) showing sustained responses and favorable survival outcomes with nivolumab (Opdivo) plus relatlimab-rmbw (Opdualag) in previously untreated patients with metastatic or unresectable melanoma signal the diminishing role for anti–PD-1 monotherapy in the frontline setting, according to Ankit Mangla, MD.
2024
RELATIVITY-048 Data Highlight Potential of Triplet ICI Regimen for Advanced Melanoma
The addition of ipilimumab (Yervoy) to nivolumab and relatlimab-rmbw (Opdualag) has generated high response rates and promising survival outcomes as a first-line treatment for patients with advanced melanoma in the phase 1/2 RELATIVITY-048 trial (NCT03459222), signifying the viability of triplet checkpoint blockade for this patient population, according to Ankit Mangla, MD. However, larger studies are needed to confirm the efficacy and safety of this approach for use in the frontline setting.
Combo immunotherapy produces distinct waves of cancer-fighting T cells with each dose
PHILADELPHIA – A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion. Findings from the use of the new tool, developed by researchers at the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center (ACC), were published today in Cancer Cell. The study challenges fundamental assumptions about how a common immunotherapy drug combination activates different types of T cells to defeat cancer and could help researchers more precisely measure immune response in future clinical trials.
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
Treatment induced sustained T-cell responses among patients with melanoma and non-small cell lung cancer.